<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01945892</url>
  </required_header>
  <id_info>
    <org_study_id>MAF/ISS/OPH/RET/011</org_study_id>
    <nct_id>NCT01945892</nct_id>
  </id_info>
  <brief_title>Dexamethasone-Implant for the Treatment of Macula Edema Due to Irvine Gass Syndrome</brief_title>
  <official_title>Ozurdex as an Treatment Option for Macula Edema Due to Irvine Gass Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To analyze macula edema formation after cataract surgery called Irvine-Gass-Syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      20 to 25 patients suffering from Irvine Gass Syndrom should be monitored for at least six
      months, controlled monthly. In all cases best corrected visual acuity, Spectralis-OCT (volume
      thickness scan), fundus photography (Optomap), intraocular pressure, slitlamp assessment and
      indirect ophthalmoscopy should be performed on every visit. Fluorescein angiography should be
      performed at baseline and after 3 and 6 months.

      Inclusion criteria:

      Patients older than 18 years who develop macula edema secondary to cataract surgery.

      - Consent agreement - Patients should be informed that it is possible to get an active
      medication (Ozurdex implant) as an &quot;on label&quot; indication from the health insurance company if
      the diagnosis is accepted as an intraocular inflammation form of &quot;Uveitis posterior&quot;.

      Exclusion criteria:

      Visual acuity worse than 20/400, known history of glaucoma and steroid response, any macular
      disease interfering with visual acuity (DME, AMD, etc.), history of vitrectomy, use of
      systemic, periocular, or intraocular corticosteroids within 30 days.

      Outcome:

        -  BCVA

        -  Patients suffering from diabetes mellitus should be evaluated also separately.

        -  Change in central retinal thickness using optical coherence tomography (OCT)

        -  Secondary parameters (elevated IOP, retinal detachments, vitreous hemorrhage,
           endophthalmitis rates)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>12 months</time_frame>
    <description>Best corrected visual acuity and visual acuity gain after 6 and 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal Thickness</measure>
    <time_frame>12 months</time_frame>
    <description>Retinal thickness measured by OCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>12 months</time_frame>
    <description>Intraocular pressure using Goldmann applanation tonometer</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">23</enrollment>
  <condition>Macular Edema</condition>
  <condition>Visual Acuity</condition>
  <arm_group>
    <arm_group_label>Irvine Gass Syndrome</arm_group_label>
    <description>Patients older than 18 years who develop macula edema secondary to cataract surgery.
Group may receive intravitreal Ozurdex medication in case of persistent macular edema.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozurdex</intervention_name>
    <description>- Consent agreement - Patients should be informed that it is possible to get an active medication (Ozurdex implant) as an &quot;on label&quot; indication from the health insurance company if the diagnosis is accepted as an intraocular inflammation form of &quot;Uveitis posterior&quot;.</description>
    <arm_group_label>Irvine Gass Syndrome</arm_group_label>
    <other_name>Dexamethasone-implant</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients older than 18 years.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients older than 18 years who develop macula edema secondary to cataract surgery

        Exclusion Criteria:

        Visual acuity worse than 20/400, known history of glaucoma and steroid response, any
        macular disease interfering with visual acuity (DME, AMD, etc.), history of vitrectomy, use
        of systemic, periocular, or intraocular corticosteroids within 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang J Mayer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LMU Munich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christos Haritoglou, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LMU Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Ophthalmology, LMU Munich</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2013</study_first_submitted>
  <study_first_submitted_qc>September 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2013</study_first_posted>
  <last_update_submitted>September 18, 2013</last_update_submitted>
  <last_update_submitted_qc>September 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Wolfgang Mayer</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>macular edema, irvine gass syndrome, ozurdex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

